Safety and efficacy of golimumab in Chinese patients with active ankylosing spondylitis: 1-year results of a multicentre, randomized, double-blind, placebo-controlled phase III trial

Rheumatology (United Kingdom)

Volumn 53, Issue 9, 2014, Pages 1654-1663

  Bao, Chunde ^a   Huang, Feng ^b   Khan, Muhammad Asim ^c   Fei, Kaiyin ^d   Wu, Zhong ^d   Han, Chenglong ^d   Hsia, Elizabeth C ^d,e  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

^d JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Ankylosing spondylitis; Asia; Biologic; China; Spondyloarthritis; Spondyloarthropathy; Tumour necrosis factor

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CORTICOSTEROID DERIVATIVE; ETHAMBUTOL; GOLIMUMAB; ISONIAZID; METHOTREXATE; PLACEBO; PYRAZINAMIDE; RIFAMPICIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANKYLOSING SPONDYLITIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASSESSMENT OF SPONDYLOARTHRITIS INTERNATIONAL SOCIETY; BATH ANKYLOSING SPONDYLITIS FUNCTIONAL INDEX; CHINESE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEMYELINATION; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; ENTERITIS; EPISTAXIS; FEMALE; FOLLOW UP; HUMAN; HYPERTRANSAMINASEMIA; INJECTION SITE ERYTHEMA; INJECTION SITE PRURITUS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OPPORTUNISTIC INFECTION; OVARY CANCER; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SERUM SICKNESS; SIDE EFFECT; SLEEP DISORDER; THORACOCENTESIS; TIBIA FRACTURE; TUBERCULOUS PLEURISY; UPPER RESPIRATORY TRACT INFECTION; UVEITIS;

EID: 84906825432     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keu132     Document Type: Article

References (26)

1. Khan MA. Ankylosing Spondylitis. New York: Oxford University Press, 2009:1-147.
2. Busquets-Perez N, Marzo-Ortega H, Emery P. Emerging drugs for axial spondyloarthritis including ankylosing spondylitis. Expert Opin Emerg Drugs 2013;18:71-86.
3. Zeng QY, Chen R, Darmawan J et al. Rheumatic diseases in China. Arthritis Res Ther 2008;10:R17.
4. Zhang S, Li Y, Deng X, Huang F. Similarities and differences between spondyloarthritis in Asia and other parts of the world. Curr Opin Rheumatol 2011;23:334-8.
5. Huang Z, Huang F. Update on the management of spondyloarthritis in Asian countries. Curr Rheum Rev 2012;8: 39-44.
6. Clegg DO, Reda DJ, Weisman MH et al. Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 1996;39:2004-12.
7. Chou C-T. The clinical application of etanercept in Chinese patients with rheumatic diseases. Mod Rheumatol 2006;16:206-13.
8. Chou C-T, Tsai C-Y, Liang T-H et al. Better short-term clinical response to etanercept in Chinese than Caucasian patients with active ankylosing spondylitis. Mod Rheumatol 2010;20:580-7.
9. Lian F, Yang X, Liang L et al. Treatment efficacy of etanercept and MTX combination therapy for ankylosing spondylitis hip joint lesion in Chinese population. Rheumatol Int 2012;32:1663-7.
10. Herman S, Krönke G, Schett G. Molecular mechanisms of inflammatory bone damage: emerging targets for therapy. Trends Mol Med 2008;14:245-53.
11. Shealy D, Cai A, Staquet K et al. Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor a. MAbs 2010;2:428-39.
12. Inman RD, Davis JC Jr, van der Heijde D et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo controlled, phase III trial. Arthritis Rheum 2008;58:3402-12.
13. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361-8.
14. Anderson JJ, Baron G, van der Heijde D, Felson DT, Dougados M. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001;44:1876-86.
15. Calin A, Garrett S, Whitelock H et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994;21:2281-5.
16. Garrett S, Jenkinson T, Kennedy LG et al. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286-91.
17. van der Heijde D, LandewéR, Feldtkeller E. Proposal of a linear definition of the Bath Ankylosing Spondylitis Metrology Index (BASMI) and comparison with the 2-step and 10-step definitions. Ann Rheum Dis 2008;67:489-93.
18. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). Conceptual framework and item selection. Med Care 1992;30:473-83.
19. Jenkins CD, Stanton B-A, Niemcryk SJ, Rose RM. A scale for the estimation of sleep problems in clinical research. J Clin Epidemiol 1988;41:313-21.
20. Zhuang Y, Xu Z, Frederick B et al. Golimumab pharmacokinetics after repeated subcutaneous and intravenous administrations in patients with rheumatoid arthritis and the effect of concomitant methotrexate: an open-label, randomized study. Clin Ther 2012;34:77-90.
21. Zhou H, Jang H, Fleischmann RM et al. Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis. J Clin Pharmacol 2007;47:383-96.
22. Conover WJ. Tests with A.R.E. of 1 or more. In: Practical Nonparametric Statistics. 2nd edn. New York: John Wiley and Sons, 1980:316-20.
23. Hsia EC, Cush JJ, Matteson EL et al. Comprehensive tuberculosis screening program in patients with inflammatory arthritides treated with golimumab, a human antitumor necrosis factor antibody, in phase III clinical trials. Arthritis Care Res 2013;65:309-13.
24. Hsia EC, Schluger N, Cush JJ et al. Interferon-g release assay versus tuberculin skin test prior to treatment with golimumab, a human anti-tumor necrosis factor antibody, in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis. Arthritis Rheum 2012;64:2068-77.
25. Vastesaeger N, van der Heijde D, Inman RD et al. Predicting the outcome of ankylosing spondylitis therapy. Ann Rheum Dis 2011;70:973-81.
26. Deodhar A, Braun J, Inman RD et al. Golimumab reduces sleep disturbance in patients with active ankylosing spondylitis: results from a randomized, placebo-controlled trial. Arthritis Care Res 2010;62:1266-71.